UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2026
Commission
File Number: 001-41493
LICHEN
INTERNATIONAL LIMITED
15th
Floor, Xingang Square, Hubin North Road,
Siming
District, Xiamen City,
Fujian
Province, China, 361013
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
INFORMATION
CONTAINED IN THIS FORM 6-K REPORT
On
November 10, 2026, Lichen International Limited, an exempted company with limited liability incorporated under the laws of the Cayman
Islands (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain
investors named thereto (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct
offering (the “Offering”),17,500,000 units (“Units”) at a purchase price of $0.20 per unit, each consisting of:
(i) one series A ordinary share, par value US$0.008 per share (the “Series A Ordinary Share”), or one pre-funded warrant
to purchase one Series A Ordinary Share (each, a “Pre-Funded Warrant” and the Series A Ordinary Shares underlying the Pre-Funded
Warrants, the “Pre-Funded Warrant Shares”) in lieu thereof, and (ii) one ordinary warrant (an “Ordinary Warrant”).
Each Ordinary Warrant is exercisable for one Series A Ordinary Share at an initial exercise price of US$0.20 per share or, at the holder’s
election and subject to its terms, through a zero-price exercise for 4.72 Class A Ordinary Shares with up to 82,600,000 Series A Ordinary
Shares (“Ordinary Warrant Shares”) issuable upon exercise of the Ordinary Warrants to purchase Series A Ordinary Shares at
a zero exercise price.
The
Offering closed on November 11, 2026. The Company received $3.5 million in gross proceeds from the Offering, before deducting placement
agent fees and estimated offering expenses. The Company intends to use the net proceeds from the Offering for working capital and general
corporate purposes.
The
Pre-Funded Warrants were sold to the Purchasers, whose purchase of the Series A Ordinary Shares in the Offering would otherwise have
resulted in the Purchasers, together with its affiliates and certain related parties, beneficially owning more than 9.99% of the outstanding
share capital of the Company following the consummation of the Offering, as elected by the Purchasers. Each Pre-Funded Warrant represents
the right to purchase one Series A Ordinary Share at an exercise price of $0.20 per share. The Pre-Funded Warrants are exercisable immediately
upon issuance, in whole or in part, and may be exercised at any time until exercised in full, subject to the beneficial ownership limitation
described above. As of the date of this Report, the Purchasers have exercised the Pre-Funded Warrants to purchase an aggregate of 13,900,000
Series A Ordinary Shares, and the Company has issued 13,900,000 Series A Ordinary Shares in accordance with the terms of the Pre-Funded
Warrants.
Each
Ordinary Warrant entitles its holder to purchase one Series A Ordinary Share at an initial exercise price of US$0.20 per share, subject
to customary adjustment and is exercisable beginning on the date of the issuance date and ending on the one year of the issuance date.
Alternatively, The Ordinary Warrants include provisions for alternative cashless exercise, pursuant to which holders of Ordinary Warrants
may effect a “zero exercise price option,” under which each Ordinary Warrant may be exercised for 4.72 Series A Ordinary
Shares, without payment of additional exercise consideration, subject to the terms of the Ordinary Warrants. Exercise is subject to a
beneficial ownership limitation of 9.99%, as elected by the Purchasers prior to issuance and subject to terms of the Ordinary Warrants.
As of the date of this Report, the Purchasers have exercised the Ordinary Warrants, pursuant to the zero exercise price option, to purchase
an aggregate of 14,986,000 Series A Ordinary Shares, and the Company has issued 14,986,000 Series A Ordinary Shares in accordance with
the terms of the Ordinary Warrants.
The
Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification
obligations of the Company, other obligations of the parties, and termination provisions.
In
addition, the Company agreed that for a period of 30 calendar days after the closing date of the Offering, it will not: (i) issue, enter
into any agreement to issue or announce the issuance or proposed issuance of any Series A Ordinary Shares or equivalent securities; or
(ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, a registration statement
on Form S-8 in connection with any employee benefit plan and the Resale Registration Statement (as defined in the Purchase Agreement.
The Company further agreed that, during the same period, it will not effect or enter into any agreement to effect any issuance of Series
A Ordinary Shares or equivalent securities involving a variable rate transaction (as defined in the Purchase Agreement) for a period
of 30 days after the closing date of the Offering, subject to certain exceptions set forth therein.
Concurrently
with the execution of the Purchase Agreement, the officers and directors of the Company entered into lock-up agreements (the “Lock-Up
Agreements”) pursuant to which they have agreed, among other things, not to sell or dispose of any Series A Ordinary Shares which
are or will be beneficially owned by them for ninety (90) days following the closing of the Offering.
The
Series A Ordinary Shares, the Pre-Funded Warrants, the Ordinary Warrants, the Pre-Funded Warrant Shares and the Ordinary Warrant Shares
(together with the Series A Ordinary Shares, the Pre-Funded Warrants, the Ordinary Warrants and the Pre-Funded Warrant Shares, the “Securities”)
were offered by the Company pursuant to a registration statement on Form F-3 (File No. 333-291878) (the “Registration Statement”),
previously filed and declared effective by the Securities and Exchange Commission (the “Commission”) on December 10, 2025,
the base prospectus filed as part of the Registration Statement, and the prospectus supplement dated November 10, 2026 (the “Prospectus
Supplement”).
On
November 10, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Univest
Securities, LLC (“Univest” or the “Placement Agent”), pursuant to which the Company engaged Univest as the sole
placement agent in connection with the Offering. The Placement Agent agreed to use its reasonable best efforts to arrange for the sale
of the Shares, the Pre-Funded Warrants and the Ordinary Warrants. In addition, under the Placement Agency Agreement the Company agreed
to pay the Placement Agent a placement agent fee in cash equal to 7.0% of the aggregate gross proceeds and a non-accountable expense
allowance equal to 1% of aggregate gross proceeds raised from the sale. The Company also agreed to reimburse the Placement Agent for
all reasonable out-of-pocket expenses, including legal and other reasonable expenses incurred by them in connection with the Offering
in an amount not to exceed $80,000.
The
Placement Agency Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Placement Agent, including for liabilities under the Securities Act of 1933, as amended
(the “Securities Act”), other obligations of the parties and termination provisions.
The
foregoing summaries of the Placement Agency Agreement, the Purchase Agreement, the Lock-Up Agreements, the Pre-Funded Warrants and the
Ordinary Warrants do not purport to be complete and are subject to, and qualified in their entirety by, such documents filed as Exhibits
10.1, 10.2, 10.3, 4.1 and 4.2, respectively, hereto and incorporated by reference herein.
Copy
of the opinion of Appleby relating to the legality of the issuance and sale of the Securities is filed as Exhibits 5.1 hereto.
Copy
of the press release related to the Offering entitled “Lichen International Limited Announces Pricing of $3.5 Million Registered
Direct Offering” is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
This
report is incorporated by reference into the registration statement on Form F-3 (File No. 333-291878) of the Company, filed with the
Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
This
report shall not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any
sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking
Statements
Certain
statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and
uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes
may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking
statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements
to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the
Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations
will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results
and encourages investors to review other factors that may affect its future results in the Company’s registration statement and
in its other filings with the U.S. Securities and Exchange Commission. Important factors that could cause our actual results and financial
condition to differ materially from those indicated in the forward-looking statements include the risks and uncertainties described in
the Company’s annual report on Form 20-F for the year ended December 31, 2025, filed with the Commission on April 28, 2026, and
the Company’s other filings with the Commission, including interim reports. The Company undertakes no obligation to publicly update
any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future
developments or otherwise.
Exhibit
Index
| Exhibit
No. |
|
Description |
| 4.1 |
|
Form of Pre-Funded Warrants |
| 4.2 |
|
Form of Ordinary Warrants |
| 5.1 |
|
Opinion of Appleby |
| 10.1 |
|
Placement Agency Agreement, dated November 10, 2026,
by and between the Company and Univest Securities, LLC |
| 10.2 |
|
Form of Securities Purchase Agreement |
| 10.3 |
|
Form of Lock-Up Agreements |
| 23.1 |
|
Consent of Appleby (included in Exhibit 5.1) |
| 99.1 |
|
Press Release |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Lichen International Limited |
| |
|
| Date: November 12, 2026 |
By: |
/s/ Ya Li |
| |
Name: |
Ya Li |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
Lichen International Limited
Announces Pricing of $3.5 Million Registered Direct Offering
XIAMEN, China, Nov. 10, 2026 (GLOBE
NEWSWIRE) -- Lichen International Limited (NASDAQ: LICN) (the “Company”), a dedicated financial and taxation service provider
in China, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase
and sale of an aggregate of 17,500,000 units (each, a “Unit”), consisting of one Class A Ordinary Share (or one pre-funded
warrant in lieu thereof) and one warrant to purchase 4.72 Class A Ordinary Shares (each, a “Warrant”), at an offering price
of $0.20 per Unit in a registered direct offering (the “Offering”).
The gross proceeds to the Company from
the registered direct offering are estimated to be approximately $3.5 Million before deducting the placement agent’s fees and
other estimated offering expenses. Each of the Warrants will have an exercise price of $0.20 per Class A Ordinary Share, will be
immediately exercisable upon issuance, and will expire on the one-year anniversary of the issuance date. The offering is expected to
close on November 11, 2026, subject to the satisfaction of customary closing conditions.
Univest Securities, LLC is acting as
the sole placement agent.
The registered direct offering
is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-291878) previously filed by the Company with the U.S.
Securities and Exchange Commission (“SEC”) and became effective on December 10, 2025. A final prospectus supplement and accompanying
prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located
at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available,
by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.
This press release does not constitute
an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies
of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus will be filed
by the Company and, upon filing, can be obtained at the SEC’s website at www.sec.gov.
About Lichen International Limited
Lichen International Limited
focuses on providing (i) financial and taxation solution services; (ii) education support services; (iii) software and maintenance services
and (iv) Pre-IPO advisory services in the PRC under our “Lichen” brand. In recognition of the Company’s expertise and
experience in the financial and taxation solution services industry for over 20 years, the Company has built up its reputation as a dedicated
financial and taxation solution services provider of professional and high-quality services in China. For more information, please visit
the Company’s website: https://ir.lichenzx.com/
Forward-Looking Statements
Certain statements in this announcement
are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on
current expectations and projections about future events and financial trends that the Company believes may affect its financial
condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by
words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,”
“continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update
forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be
required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable,
it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may
differ materially from the anticipated results and encourages investors to review other factors that may affect its future results
in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.
For investor and media inquiries,
please contact:
LICHEN INTERNATIONAL LIMITED
Tian Sun
Phone: +86-592-5586999
Email: ir@lichenzx.com